Compound class:
Synthetic organic
Comment: The structure for tacaciclib was obtained from proposed INN list 129 (August 2023), where it is described as cyclin-dependent kinase inhibitor and antineoplastic agent. The structure is calimed in patent WO2022130304A1, for potential to treat cancer or other proliferative diseases that are mediated by CDK7 [1]. Interogation of online information suggests that this compound may be XL102 (formerly AUR102), an orally bioavailable covalent CDK7 inhibitor that was acquired by Exelixis, from Aurigene, in late 2020.
|
|
No information available. |
Summary of Clinical Use |
XL102 has entered clinical evaluation. It is proposed as a therapy for advanced solid tumours. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Phase 1 Interventional | Exelixis |